Recruiting Intergroup trials coordinated by the EORTC

Protocol
Title
Coordinating Group
1203INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

Study Coordinator:

Anna Dorothea Wagner, Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

EORTC Gastrointestinal Tract Cancer Group
1206A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)

Study Coordinator:

Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

EORTC Head and Neck Cancer Group
130110-day decitabine versus conventional chemotherapy (3+7) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Study Coordinator:

Pierre W. Wijermans, HagaZiekenhuis - locatie Leyweg, 'S Gravenhage - Den Haag

Michael Luebbert, Universitaetsklinikum Freiburg, Freiburg

Gerwin Huls, Radboud University Medical Center Nijmegen, Nijmegen

EORTC Leukemia Group
1333A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Study Coordinator:

Bertrand Tombal, Cliniques Universitaires Saint-Luc, Brussels

EORTC Genito-Urinary Cancers Group
1401Management of low risk ductal carcinoma in situ (low-risk DCIS): a randomized, multicentre, non-inferiority trial, between standard therapy approach versus active surveillance

Study Coordinator:

Pieter Wesseling, Radboud University Medical Center Nijmegen, Nijmegen

Jelle Wesseling, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam

EORTC Breast Cancer Group
1409A prospective Colorectal Liver Metastasis DataBase with an Integrated Quality Assurance program

Study Coordinator:

Serge Evrard, Institut Bergonie, Bordeaux

Graeme Poston, Royal Liverpool University Hospital, Liverpool

EORTC Gastrointestinal Tract Cancer Group
1416A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy

Study Coordinator:

Mary O'Brien, Royal Marsden Hospital - Chelsea, London, London

EORTC Lung Cancer Group
1419Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma

Study Coordinator:

Michael Weller, UniversitaetsSpital Zurich, Zurich

EORTC Brain Tumor Group
1527Diffusion-Weighted Magnetic REsonance Imaging Assessment of Liver Metastasis and Improve Surgical Planning

Study Coordinator:

Serge Evrard, Institut Bergonie, Bordeaux

EORTC Gastrointestinal Tract Cancer Group
62113 A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Study Coordinator:

Isabelle Ray Coquard, Centre Leon Berard, Lyon

EORTC Soft Tissue and Bone Sarcoma Group